GISAR has an open and modular setup. It is sought to include as many German sarcoma and CS patients (i.e. sarcoma and CS patients treated in Germany) in the registry as possible. A basic data set should be collected on every included patient). In order to adress specific scientific questions, additionally detailed data can be collected in defined patient groups (e.g. effectiveness / adverse effects of systemic therapies in defined situations) within the context of sub-project add-on modules. This data collection can be prospective or retrospective depending on the sub-project
Sarcomas are rare malignant tumors that affect people of all ages. They can be divided into different subtypes yet having more than 80 different forms of soft tissue sarcomas only. In these terms, it is not remarkable that this high number of subtypes is accompanied by various treatment strategies, often representing multimodal treatments. In addition, in a growing amount of patients tumors are diagnosed, whose malignant cells have histological, cytological, or molecular properties of both epithelial tumors ("carcinoma") and mesenchymal tumors ("sarcoma"). Such "mixed" sarcomatoid/epithelial tumors ("CS") are categorized as carcinoma considering their epithelial origin. But in most cases, CS seem to be more aggressive, than other carcinomas with the same origin; often they are characterized by rapid growth, invasion, disease recurrence and metastases. Due to the rarity of CS, only limited information is available about their clinical course and best therapeutic approaches. Because of these uncertainties and the sarcoma-component of the tumors, several CS-patients are referred to sarcomacenters. As many experiences with single CS-cases as possible should be collected and evaluated to better understand the different CS-forms. Due to the complexity of diagnosis and therapy of sarcomas and of CS it is of high relevance to depict the current treatment landscape and the effects and course of different treatment options to illuminate the best option for each specific patient. This is compassed by this registry, as it aims to collect information and data on treatment and outcome of most of future German sarcoma cases along with retrospective data collection to achieve a most comprehensive data set as well as the possibility to identify alterations / trends in the procedures used for sarcoma diagnosis and therapy over time.
Study Type
OBSERVATIONAL
Enrollment
9,000
Universitätsklinikum Tübingen
Tübingen, Baden-Wurttemberg, Germany
RECRUITINGUniversitätsklinikum Erlangen
Erlangen, Bavaria, Germany
RECRUITINGHELIOS Klinikum Bad Saarow
Bad Saarow, Germany
RECRUITINGHELIOS Klinikum Berlin-Buch
Berlin, Germany
RECRUITINGVivantes Klinikum Berlin-Spandau
Berlin-Spandau, Germany
RECRUITINGUniversitätsklinikum Erlangen
Erlangen, Germany
RECRUITINGKlinikum Frankfurt Höchst
Frankfurt, Germany
RECRUITINGKrankenhaus Nordwest KHNW
Frankfurt, Germany
RECRUITINGUniklinik Freiburg
Freiburg im Breisgau, Germany
RECRUITINGUniversitätsmedizin Göttingen
Göttingen, Germany
RECRUITING...and 11 more locations
Incidence of sarcoma preferably specific to the different subtypes
Generation of epidemiological data
Time frame: 1 year
Prevalence of sarcoma preferably specific to the different subtypes
Generation of epidemiological data
Time frame: 1 year
Prognosis of sarcoma preferably specific to the different subtypes
Generation of epidemiological data
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.